Proactive Investors - Run By Investors For Investors

WideCells' financing draws a line under funding needs says CEO Andrade

WideCell PLC’s (LON:WDC) chief executive Joao Andrade explains why the latest financing draws a line under the stem cell business’s funding needs and how it will recover from here.

The money enables us to focus solely on the sale of our insurance product, CellPlan, and the stem cell processing and storage service, he tells Proactive.

It has been a challenging year, but a learning curve for the group but the group understands now how long it takes both to launch a product and to ramp up sales.

Year-end results will start to show the benefits, he adds.

Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full WDC profile View Profile

WideCells Group Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use